Intraoperative imaging techniques have the potential to make surgical interventions safer and more effective; for these reasons, such techniques are quickly moving into the operating room. Here, we present a new approach that utilizes a technique not yet explored for intraoperative imaging: chemiluminescent imaging. This method employs a ruthenium-based chemiluminescent reporter along with a custom-built nebulizing system to produce an ex vivo or in vivo images with high signal-to-noise ratios. The ruthenium-based reporter produces light following exposure to an aqueous oxidizing solution and re-reduction within the surrounding tissue. This method has allowed us to detect reporter concentrations as low as 6.9 pmol/cm². In this work, we present a visual guide to our proof-of-concept in vivo studies involving subdermal and intravenous injections in mice. The results suggest that this technology is a promising candidate for further preclinical research and might ultimately become a useful tool in the operating room.
biomedical imaging is therefore a rather unexplored area of research that could offer the following advantages: (1) minimal autofluorescence resulting in a low background signal with higher signal-to-noise ratios; (2) tunable wavelengths of chemiluminescent emissions ranging from the visible to the near-infrared; and (3) functionalizable chemiluminescent complexes that, when combined with linker technologies and targeted biomolecules that already exist, provide access to whole libraries of targeted molecular imaging probes\textsuperscript{14}.

This proof-of-principle study illustrates the potential utility of chemiluminescent imaging in the biomedical setting using a ruthenium-based imaging agent. The chemiluminescent properties of this compound are well studied, with investigations dating back to the mid-1960s\textsuperscript{15}. Upon chemical activation, the agent produces light at around 600 nm\textsuperscript{16}, which is well suited for medical imaging purposes. The activation energy is provided by a redox reaction that leads to an excited state—which has a lifetime of 650 ns in water\textsuperscript{17}—followed by the generation of photons upon relaxation of this excited state. Through the use of a specially-designed remote nebulizer, we were able to detect the compound both ex vivo and in vivo. The results of initial experiments are very promising, suggesting further investigation of this technology.

---

### Protocol

**Ethics statement:** All of the *in vivo* animal experiments described were performed according to an approved protocol and under the ethical guidelines of the Memorial Sloan Kettering Cancer Center (MSK) Institutional Animal Care and Use Committee (IACUC).

#### 1. Construction of a Nebulizing Device

1. Attach wood part A (12.5 x 2.5 x 1.8 cm\textsuperscript{3}) upright in the center of part B (12.7 x 10.7 x 1.8 cm\textsuperscript{3}) using two screws (4 x 25 mm\textsuperscript{2}). Attach wood part C (11 x 2.5 x 1.8 cm\textsuperscript{2}) to the middle of part A (12.5 x 2.5 x 1.8 cm\textsuperscript{2}) using one screw, such that part C (11 x 2.5 x 1.8 cm\textsuperscript{2}) can still be moved. See Figure 1.
2. Drill two holes through the lower tip of the spray bottle trigger of a plastic 3 oz mini sprayer (D) and push a stainless steel rod (10 cm of 1/16” steel) (E) through to form two loops, one on each side of the trigger.
3. Wrap the bottom part of the spray bottle with duct tape (F) to prevent the cable ties from slipping off. Attach the spray bottle to wood part C (11 x 2.5 x 1.8 cm\textsuperscript{2}) using the two plastic cable ties (28 cm) (G).
4. Cut off the wire servo motor (I) and reconnect it with the loose cables of the servo control (H). Then, attach the servo motor to the top of wood part A (12.5 x 2.5 x 1.8 cm\textsuperscript{2}) using duct tape.
5. Attach a pencil (J) to the servo motor lever using the paper clip (K). Tightly connect the outermost parts of the pencil to the steel rod loops using plastic covered twist wires (L) and secure the ends on the pencil with duct tape.
6. Cut off the servo motor control unit’s magnetic cable connector (M) and reattach it to the speaker cable (N). Then, tape the servo motor control unit to wood part B (12.7 x 10.7 x 1.8 cm\textsuperscript{3}). Cut a w1 cable with magnetic connectors in half and attach one part to the loose end of the copper speaker cable (1 m). Connect the (magnetic) I2 toggle switch and p1 power to the available w1 cable and a 9V battery.

#### 2. Sensitivity Determination of the Method

1. In a 1.5 mL microcentrifuge tube, prepare solutions of [Ru(bpy)\textsubscript{3}]\textsubscript{2}\textsuperscript{2+} in reverse osmosis water (100 µL) in amounts of 260 µg (347 nmol), 52 µg (69 nmol), 26 µg (34 nmol), 5 µg (6.9 nmol), 3 µg (3.5 nmol), 520 ng (694 pmol), 260 ng (347 pmol), 52 ng (69 pmol), 26 ng (34 pmol), 5 ng (6.9 pmol), and 3 ng (3.5 pmol).
2. Mix 100 µL of each [Ru(bpy)\textsubscript{3}]\textsubscript{2}\textsuperscript{2+} solution with 100 µL of an aqueous solution of ammonium cerium nitrate ((NH\textsubscript{4})\textsubscript{3}Ce(NO\textsubscript{3})\textsubscript{6}) in water (25 mM) on a microscope slide.
3. **Set up the acquisition in the bioluminescence reader by initializing the imaging software.**
   1. Sign in to the user profile and look for the acquisition control panel. Click on “Initialize” and wait until the instrument is ready.
   2. Look for “Imaging Mode” and make sure “Luminescent” and “Photograph” are checked and that “Fluorescent” is unchecked.
   3. Change “Exposure Time” setting for “Luminescent” to 20 s. Set the remaining settings for “Luminescent” as follows: “Binning”: Medium; “F/stop”: 1; and “Emission Filter”: Open.
   4. For “Photograph,” use the following settings: “Exposure Time”: Auto; “Binning”: Medium; and “F/stop”: 8. Adjust the “Subject Height” according to imaging target.
4. **Set up the nebulizer by placing a microscopic slide on a sheet of black construction paper on the floor of the imaging chamber to protect it from the oxidizing agent. Mix a 100 µL droplet of [Ru(bpy)\textsubscript{3}]\textsubscript{2}\textsuperscript{2+} solution with 100 µL of an aqueous solution of (NH\textsubscript{4})\textsubscript{3}Ce(NO\textsubscript{3})\textsubscript{6}.**
   1. Place the imaging subject on the black construction paper, such that the area of interest is in the center of the green light box crosshair displayed on the sample stage. Prepare the nebulizer by detaching the plastic spray bottle from the wooden support. Fill a solution of triethylamine (1:3 in water/ethanol) into its plastic reservoir and reattach it to the wooden support.
   2. Place the nebulizer inside the bioluminescence reader and make sure that the power cord is disconnected from the nebulizer cord.
   3. Ensure that the power switch is on, the toggle switch is off, and the red LED is lit. Place the nebulizer such that the spray flow is pointed towards the area of interest on the imaging subject, while minimizing the view obstruction from the camera towards the imaging subject by the spray nozzle head.
   4. Place small, black pieces of construction paper over any potential hot spots (e.g., white marks on microscopic slides or injection sites) to shield them from spray. Place at least 40 cm of the nebulizer remote cord inside the imaging chamber, such that it does not interfere with the imaging subject, the nebulizer, or the magnetic door latch. Close the imaging system door.
   5. **See Figure 2.**

---

\textsuperscript{17} Denys, A. et al. J. Am. Chem. Soc. 131, 13790-13791 (2009).
Representative Results

3. In Vivo Imaging After Systemic Intravenous Injection

1. In a 1.5 mL microcentrifuge tube, prepare 100 µL of phosphate-buffered saline (PBS) solution containing between 8 and 33 nmol of [Ru(bpy)_3]Cl_2. Prepare an aqueous solution of (NH_4)_2Ce(NO_3)_6 in water (25 mM) at the same time.

2. Intravenously inject 100 µL of [Ru(bpy)_3]Cl_2 into the tail vein of healthy mice (n = 5).

3. Euthanize the mice 10 min after injection via CO_2 asphyxiation.
   1. Remove the skin with a Y-cut from the torso, then remove the costal arch in a U-shape to expose the heart and lungs. Perfuse the mice by cutting an outlet in the right atrium and injecting 20 mL of PBS through a 24 gauge needle into the left ventricle\(^{18}\). Carefully cut through the belly skin and expose the kidney and liver. Cut longitudinally through the organs to create a visible cut.

4. Set up the acquisition as described in steps 2.3-2.6, with the following changes.
   1. After thoroughly washing the nebulizer plastic reservoir, fill it with a solution of (NH_4)_2Ce(NO_3)_6 in water (25 mM) instead of triethylamine.

5. Use the whole animal or organ samples for imaging.
   1. For whole abdomen imaging, position the mouse carcass with the open abdomen facing the camera and the head pointing to the back of the instrument. Center the organ to be imaged (e.g., liver or kidney) in the green light box crosshair.
   2. For individual organ imaging and quantification, remove the mouse from the imaging instrument and pin it down. Starting from the already-opened body cavity, excise the inner organs (e.g., kidney, liver, lung, muscle, spleen, brain, and heart). Cut through the hind leg skin to excise muscle tissue. Carefully open the skull with a scalpel to excise the brain.
      1. If the organ of interest is liver, kidney or spleen, cut all organs in half longitudinally, place each organ on a petri dish or piece of black construction paper.
   3. Follow the procedure described in steps 2.3-2.6 to establish the relative emission of the chemiluminescent tracer for single organs.

4. In Vivo Imaging of Lymph Nodes

1. Prepare 10 µL of a PBS solution containing 80 nmol of [Ru(bpy)_3]Cl_2. Prepare an aqueous solution of (NH_4)_2Ce(NO_3)_6 in water (25 mM) at the same time.

2. Inject 10 µL of the solution subdermally into the hind paw of healthy mice (n = 5). As a negative control, inject the contralateral paw with 10 µL of pure PBS. Sacrifice the mice via CO_2 asphyxiation 15 min after the injection. Remove the skin on both hind legs to expose the lymph canals up to the popliteal lymph nodes.

3. Set up the acquisition as described in step 3.4.

4. Remove the popliteal lymph nodes from both hind legs, cut them in half, and spray them with oxidant on a Petri dish, as described before (step 3.5.3), for the purpose of quantification.

The nebulizer system described in protocol section 1 can be constructed from easily-available materials at a low cost. It is intended to be an insert for remote-triggered spraying of the reducing/oxidizing agent inside a bioluminescent reader (Figure 1). Our design allows for the safe operation of the nebulizer within the bioluminescence reader at a 14 cm distance from the lens. No fogging or blurring of the lens was observed during the operation. We selected the commercially-available chemiluminescent agent [Ru(bpy)_3]Cl_2 for the development of our method based on its low price, stability in aqueous solution, well-described redox behavior, and chemiluminescent properties (Figure 2)\(^{19}\). The minimal detectable signal can be determined as described in protocol section 2 by oxidizing one drop of [Ru(bpy)_3]Cl_2 (100 µL, 6.9 pmol- 347 nmol in H_2O) with (NH_4)_2Ce(NO_3)_6 (100 µL, 25 mM) on a microscope slide. Then, by using the nebulizer and spraying on a solution of triethylamine (1:3 in water/ethanol), the chemiluminescent signal is triggered. In our case, the minimal detectable signal was determined to be 6.9 pmol/cm\(^2\) (Figure 3). It is conceivable, though, that optimized reaction conditions, camera sensitivities, shutter times, volumes, and reagent concentrations might lead to even lower detection thresholds. These reaction conditions can also be used for exploring and testing the chemiluminescence of any given combination of metal complexes, oxidizing agents, and reductants.
Moving to the in vivo experiments in protocol sections 3 and 4, female nude (outbred) mice 5-6 weeks old and Nu/J male mice 6-8 weeks old were used. For intravenous injections, amounts of 8-33 nmol of \([\text{Ru}(\text{bpy})_3]\text{Cl}_2\) in 100 µL of PBS per mouse (n = 5) were chosen. The animals were sacrificed 10 min after injection, and the abdominal cavity was exposed. The mice were placed in the bioluminescent reader with the nebulizer pointing towards the tissue of interest (Figure 4). For imaging with intravenously-injected \([\text{Ru}(\text{bpy})_3]\text{Cl}_2\), the chemiluminescent signal was detected predominantly in the kidneys, strongly suggesting renal elimination of the hydrophilic small molecule (Figure 5). Signal-to-noise ratios for mice injected with \([\text{Ru}(\text{bpy})_3]\text{Cl}_2\) versus PBS were 27/1 for the kidney and 21/1 for the liver. For lymph node imaging, 80 nmol of \([\text{Ru}(\text{bpy})_3]\text{Cl}_2\) in 10 µL of PBS were injected subdermally into the hind foot pad of mice (n = 5). Mice were sacrificed 15 min post injection by CO\(_2\) asphyxiation. The skin covering both the inner hind legs was removed to expose the muscle, lymph nodes, and lymphatic vessels. Subsequent chemiluminescent visualization of the popliteal lymph nodes led to the observation that lymph nodes containing \([\text{Ru}(\text{bpy})_3]\text{Cl}_2^{2+}\) show a 10 ± 4.3-fold higher radiance than untreated ones (167,000 p/(s×cm\(^2\)×sr) and 17,000 p/(s×cm\(^2\)×sr); P <0.028) (Figure 6).

Figure 1: Photograph of the Nebulizer. Parts used: Wooden structure parts (A, B, C), spray bottle (D), bent steel rod (E), duct tape (F), plastic cable ties (G), 011 servo connector part (H), servo motor (I), pencil (J) held by bent paper clip (K), plastic covered wire twist ties (L) w1 wire connector (M) and speaker cable (N) leading to the battery. This figure is based on research originally published in reference 19. Please click here to view a larger version of this figure.

Figure 2. Properties of \([\text{Ru}(\text{bpy})_3]\text{Cl}_2^{2+}\). Structure (A) and excitation and emission spectra (B) of \([\text{Ru}(\text{bpy})_3]\text{Cl}_2^{2+}\). The oxidation/reduction based chemiluminescent catalytic cycle (C). This figure is based on research originally published in reference 19. Please click here to view a larger version of this figure.

Figure 3: Detection Threshold of \([\text{Ru}(\text{bpy})_3]\text{Cl}_2^{2+}\). Representative signal intensities at different concentrations of \([\text{Ru}(\text{bpy})_3]\text{Cl}_2^{2+}\) on a microscope slide (A). Imaging signal quantification with detection threshold (red dotted line) and background (black dotted line) (B). This figure is based on research originally published in reference 19. Please click here to view a larger version of this figure.
Figure 4: Chemiluminescence Imaging. Schematic drawing of a mouse and a nebulizer positioned in the bioluminescence reader (A) and schematic drawing (B) of the nebulizer spraying on a mouse. This figure is based on research originally published in reference 19. Please click here to view a larger version of this figure.

Figure 5: Detection of $[\text{Ru(bpy)}_3]^{2+}$ after Systemic Administration. White light, chemiluminescence, and overlay (from left to right). Images of a mouse body cavity that was injected with 33 nmol of $[\text{Ru(bpy)}_3]^{2+}$ and sprayed with $(\text{NH}_4)_2\text{Ce(NO}_3)_6$. The white arrow points towards the right kidney. This figure is based on research originally published in reference 19. Please click here to view a larger version of this figure.

Figure 6: Detection of $[\text{Ru(bpy)}_3]^{2+}$ after Subdermal Administration. Popliteal lymph node imaging showing white light, chemiluminescence, and composite pictures for mice injected with $[\text{Ru(bpy)}_3]^{2+}$ (top) and PBS (bottom) in the hind limbs; 80 nmol in 10 µL of PBS, imaged 15 min after injection (A). White light and composite images for $[\text{Ru(bpy)}_3]^{2+}$ (top) and PBS (bottom)-treated excised popliteal lymph nodes (B). Quantification of chemiluminescent signals for PBS and $[\text{Ru(bpy)}_3]^{2+}$-treated lymph nodes (C). The data represents the mean ± SD. This figure is based on research originally published in reference 19. Please click here to view a larger version of this figure.

Discussion

Here, we have presented a technology that is capable of optically delineating tissue via the emission of photons created by a chemiluminescent reporter. In contrast to other, more established technologies, this chemiluminescent reporter system employs an imaging probe that is non-radioactive and facilitates detection at very high sensitivity levels. Perhaps even more importantly, chemiluminescence imaging does not require an incident light source (as in optical fluorescence imaging), a trait that minimizes autofluorescence and drastically reduces background signals.

The ruthenium reporter $[\text{Ru(bpy)}_3]^{2+}$ has an in vivo toxicity tolerable for imaging purposes (intraperitoneal mouse LD$_{50}$: 20 mg/kg)\textsuperscript{21}, is water soluble (up to 8 mM), and is stable in the bloodstream. The physicochemical properties of the metal complex are well-characterized and have already been investigated for the photodynamic therapy of cancer\textsuperscript{22,23}. The oxidizing agent $(\text{NH}_4)_2\text{Ce(NO}_3)_6$ has been reported to have very low toxicity (oral rat LD$_{50}$: 1600-3200 mg/kg)\textsuperscript{24} and is soluble in water at concentrations of up to 2.57 M at 20 °C\textsuperscript{25}. In this article, visual demonstration as well as text-based guidance for the construction of a remotely-operated nebulizing device are presented. In addition, we
provide robust protocols for performing chemiluminescence imaging in a standard bioluminescence imaging device. We illustrate the use of 
[Ru(bpy)3]Cl2 for the visualization of tissues after both intravenous and subdermal injections in mice.

However, as with any other nascent imaging technology, there is room for improvement of our protocols. We believe that this proof-of-principle study could spur the development of multiple chemiluminescence applications for living systems. The following points could be addressed to further improve the technology and expand its scope.

A smaller second generation of remotely triggered spraying devices would allow the sample to be closer to the camera, hence improving spatial resolution. Improved optical equipment might further improve the detection limits of the method. The protocol could also be extended to imaging live animals. Exact control of the torque (by current and voltage) would allow a more exact control of the volume of reagent released with each spray. It is important to keep the nebulizer well-maintained. Not rinsing the nebulizer may destroy the nozzle. A fresh battery is crucial for the proper performance of the nebulizer. However, all the materials used for the nebulizer are inexpensive and readily commercially available. Following established synthetic protocols, the [Ru(bpy)3]2+ complex can easily be modified with various linkers, including maleimides26, amines27, and NHS esters28, 29. This would enable bioconjugation to small molecules, peptides, or antibodies, and would thus facilitate specific molecular targeting30, 31, 32, 33. Ultimately, targeted probe delivery could enable surgeons to identify small lesions and to accurately delineate surgical margins in the operating room with very high specificity. Also, the encapsulation of the highly water-soluble [Ru(bpy)3]2+ in nanomaterials both targeted and untargeted may also allow for the visualization of lesions while they are being surgically removed34, 35, 36, 37. Finally, modifying the coordination sphere of the metal complex reporter and/or changing the transition metal center itself represent attractive routes to modulate and fine-tune the emission wavelengths within the visible and NIR ranges37, 38.

Intraoperative chemiluminescence imaging needs a chemiluminescent reporter and, in our case, an oxidant, which can only be used within the limits of their toxicity and solubility. Tissue membranes can represent a barrier for the diffusion of the oxidant into the tissue, and hence, the signal generation. Since the chemiluminescent reporter is only generating one photon per cycle, the generated signal is rather weak. The ambient light in the operating room will therefore have to be prevented from entering the camera while the technique is in use. This might render IC1 particularly interesting for the development of laparoscopic applications, where ambient light is naturally excluded.

We hope that this method may turn into a valuable tool for surgeons in the operating room. The absence of radioactivity is beneficial to the patient and operating team alike and makes fewer safety precautions necessary, potentially rendering this technique into a more attractive alternative.

The smooth operation of the nebulizer and its positioning play a crucial role for obtaining good results. Suboptimal angles and areas may contribute to signal variance. The control cable must be put through the door with care, and enough cable has to remain inside the bioluminescence reader so that it is not cramped or torn off.

Ultimately, chemiluminescence imaging is an extremely attractive new approach to molecular imaging. It is based on a foundation of well-established chemistry, employs inexpensive and readily available materials, and eschews both radiation and excitation light sources. As a result, we are both hopeful and confident that in the future, chemiluminescence imaging could have a profound effect on the surgical treatment of disease.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors thank Prof. Jan Grimm and Mr. Travis Shaffer for their helpful discussions and Mr. David Gregory for editing the manuscript. Technical services provided by the MSK Animal Imaging Core Facility, supported in part by NIH Cancer Center Support Grant P30CA08748-48, are gratefully acknowledged. The authors thank the NIH (K25 EB016673 and R21 CA191679, T.R. and 4R00CA178205-02, B.M.Z.), the MSK Center for Molecular Imaging and Nanotechnology (T.R.), the Tow Foundation (B.C.), and the National Science Foundation Integrative Graduate Education and Research Traineeship (IGERT 0965983 at Hunter College for B.C. and T.M.S.) for their generous support. The research reported in this publication was supported by funding from the King Abdullah University of Science and Technology.

References
